ISCL/EORTC revision to the staging of MF and SS
| . | T . | N . | M . | B . |
|---|---|---|---|---|
| IA | 1 | 0 | 0 | 0,1 |
| IB | 2 | 0 | 0 | 0,1 |
| IIA | 1,2 | 1,2 | 0 | 0,1 |
| IIB* | 3 | 0-2 | 0 | 0,1 |
| III* | 4 | 0-2 | 0 | 0,1 |
| IIIA* | 4 | 0-2 | 0 | 0 |
| IIIB* | 4 | 0-2 | 0 | 1 |
| IVA1* | 1-4 | 0-2 | 0 | 2 |
| IVA2* | 1-4 | 3 | 0 | 0-2 |
| IVB* | 1-4 | 0-3 | 1 | 0-2 |
| . | T . | N . | M . | B . |
|---|---|---|---|---|
| IA | 1 | 0 | 0 | 0,1 |
| IB | 2 | 0 | 0 | 0,1 |
| IIA | 1,2 | 1,2 | 0 | 0,1 |
| IIB* | 3 | 0-2 | 0 | 0,1 |
| III* | 4 | 0-2 | 0 | 0,1 |
| IIIA* | 4 | 0-2 | 0 | 0 |
| IIIB* | 4 | 0-2 | 0 | 1 |
| IVA1* | 1-4 | 0-2 | 0 | 2 |
| IVA2* | 1-4 | 3 | 0 | 0-2 |
| IVB* | 1-4 | 0-3 | 1 | 0-2 |
B, blood; M, metastasis; N, node; T, tumor.
Considered “advanced-stage” disease.